Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand.
about
Use of altered peptide ligands to modulate immune responses as a possible immunotherapy for allergies.Computational analysis of T cell receptor signaling and ligand discrimination--past, present, and future.A CD4+ T cell antagonist epitope down-regulates activating signaling proteins, up-regulates inhibitory signaling proteins and abrogates HIV-specific T cell function.Multi-modal antigen specific therapy for autoimmunity.Sensitivity of T cells to antigen and antagonism emerges from differential regulation of the same molecular signaling module.Purely stochastic binary decisions in cell signaling models without underlying deterministic bistabilities.Versatility of using major histocompatibility complex class II dextramers for derivation and characterization of antigen-specific, autoreactive T cell hybridomasTh2 cell clonal anergy as a consequence of partial activation.Modulation of T cell development by an endogenous altered peptide ligandMyocarditis-inducing epitope of myosin binds constitutively and stably to I-Ak on antigen-presenting cells in the heart.Endogenous altered peptide ligands can affect peripheral T cell responses.Selective activation of Fas/Fas ligand-mediated cytotoxicity by a self peptideStructural basis for T cell recognition of altered peptide ligands: a single T cell receptor can productively recognize a large continuum of related ligandsA kinetic threshold between negative and positive selection based on the longevity of the T cell receptor-ligand complex.Partially phosphorylated T cell receptor zeta molecules can inhibit T cell activation.Costimulation of T cell activation by integrin-associated protein (CD47) is an adhesion-dependent, CD28-independent signaling pathway.Stochastic effects and bistability in T cell receptor signalingMonitoring the Dynamics of T Cell Clonal Diversity Using Recombinant Peptide:MHC Technology.F(c)gammaRI-targeted fusion proteins result in efficient presentation by human monocytes of antigenic and antagonist T cell epitopesKinetic discrimination in T-cell activation.Functional inhibition related to structure of a highly potent insulin-specific CD8 T cell clone using altered peptide ligands.Magnitude of activity in chronic hepatitis C is influenced by apoptosis of T cells responsible for hepatitis C virus.The good, the bad and the ugly: how altered peptide ligands modulate immunity
P2860
Q33987217-1DDA28C4-E307-416B-96D1-4D77D6F5E295Q34388307-204A017B-1C7F-46B1-9817-468F306D9774Q34486338-409D181F-1CD5-4823-8DBB-7E3B28EBCCE5Q34560522-91008017-C68D-4DC6-AADC-966299143F8FQ35720467-D1632490-0164-4939-9C09-79796824754CQ36277148-F8832D38-94DF-4563-A8FE-4EB5CEA1639DQ36296691-1F5B43E0-1A1E-44FC-880C-FD8C3EEB805FQ36363894-DB76C406-83D8-4CBF-A00A-945ADA564CC3Q36364377-F318E072-3BDE-4F50-8126-2489CBAF5C9DQ36365501-DDA48FA6-2C89-4881-840D-BDE3B8CC6717Q36366390-5ADFD9DF-3DF6-4F1D-AF79-43BBC848240FQ36366862-5E4167CD-F9D2-4528-8FDE-96E99AD6C5D0Q36367500-0151DE3F-07DF-4CD8-9B38-DC291D41AFC2Q36369989-3A39ED29-FDE2-405E-93E3-89736BBBC321Q36375671-BCB9091F-5CD8-45C2-BF8F-83CD5522FD28Q36398329-AA7B7905-90F4-485C-A518-8DE1F29E8A61Q36958563-05DAA4D8-4548-4E58-95FB-39D11393F3DEQ36977064-A5E96DCE-7423-441C-B056-4229D15D6983Q37360991-93E2D3CA-56D4-4679-B48A-535D7D8BAD91Q37715642-CD6AFD0B-ACAE-422F-B4D1-3BE7600B29B4Q42735278-D3B02E05-8300-4536-9FD9-C7CBAC558BB3Q42995594-70B395B5-FDD4-48B4-9C5F-C856E22EAC3DQ57594274-20751F10-AF45-4510-A56C-EF23409365D1
P2860
Antagonism of superantigen-stimulated helper T-cell clones and hybridomas by altered peptide ligand.
description
1994 nî lūn-bûn
@nan
1994 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մարտին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Antagonism of superantigen-sti ...... mas by altered peptide ligand.
@ast
Antagonism of superantigen-sti ...... mas by altered peptide ligand.
@en
type
label
Antagonism of superantigen-sti ...... mas by altered peptide ligand.
@ast
Antagonism of superantigen-sti ...... mas by altered peptide ligand.
@en
prefLabel
Antagonism of superantigen-sti ...... mas by altered peptide ligand.
@ast
Antagonism of superantigen-sti ...... mas by altered peptide ligand.
@en
P2093
P2860
P356
P1476
Antagonism of superantigen-sti ...... mas by altered peptide ligand.
@en
P2093
B D Evavold
J Sloan-Lancaster
P2860
P304
P356
10.1073/PNAS.91.6.2300
P407
P577
1994-03-01T00:00:00Z